Evoke Pharma receives USPTO Notice of Allowance for GIMOTI patent extending exclusivity to 2036

Evoke Pharma Inc

USPTO allowed patent covering GIMOTI use in moderate-to-severe gastroparesis; expected to expire Dec 2036.
Patent is continuation of U.S. Patent No. 11,517,545; extends Orange Book exclusivity ~6 years beyond existing patents.
Company plans to list patent in FDA Orange Book upon issuance; filed another continuation application for additional claims.
GIMOTI is only FDA-approved non-oral self-administered metoclopramide for diabetic gastroparesis.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.